CymaBay
is a California-based biopharmaceutical company that discovers and develops novel therapies for the treatment of liver and chronic diseases... Read moreCymaBay
is a California-based biopharmaceutical company that discovers and develops novel therapies for the treatment of liver and chronic diseases... Read more
1988
PublicAcquired by Gilead Sciences, Inc.NASDAQCBAY
News
Jun 12, 2024
Endpoints News
CymaBay: Gilead's M&A appetite is for deals in the 'mid-single-digit billions," CEO says
Jun 06, 2024
Medthority
CymaBay: Seladelpar demonstrated a sustained and consistent long term efficacy and safety profile in primary biliary cholangitis
Jun 05, 2024
MarketScreener
CymaBay: CymaBay Therapeutics : Assessment of PPAR-delta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar
May 13, 2024
Emerging Growth
Press Release: CymaBay : Gilead Acquisition of CymaBay Rekindles Interest in Liver Disease
Apr 25, 2024
Saltwire
CymaBay: Gilead posts quarterly loss, revenue rises 5% | SaltWire
Mar 26, 2024
ExploreBit
CymaBay: Gilead Sciences Completes Acquisition CymaBay
Mar 25, 2024
Pharamceutical Technology
CymaBay: Gilead acquires CymaBay Therapeutics for $4.3bn
Mar 25, 2024
FinSMEs
CymaBay: Gilead Sciences Completes Acquisition of CymaBay, for Approximately $4.3 Billion
Mar 22, 2024
MarketScreener
CymaBay: CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K
Mar 06, 2024
Pharmabiz
CymaBay: EMA accepts for review CymaBay's marketing authorization application for seladelpar to treat primary biliary cholangitis
CymaBay Competitors
1
2
3
4
5
6
7
8
9
10